AI assistant
USCOM LIMITED — Regulatory Filings 2015
Nov 3, 2015
65979_rns_2015-11-03_a24f3e7e-bd56-443d-9269-dd6b384ed879.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au
M A R K E T A N N O U N C E M E N T
Uscom Establishes UK Subsidiary
SYDNEY, Australia, Wednesday 4th November 2015: Uscom Limited (ASX code: UCM) (the Company or Uscom ), a cardiovascular and pulmonary medical devices company, today announced the establishment of a wholly owned UK subsidiary based in London. The entity is registered as Uscom Medical Limited (Uscom Medical).
The establishment of the UK entity is the next decisive step in the global expansion of Uscom and extends its strategic reach into the European and US markets in response to increased global demand. This expansion also follows the acquisition of Thor Laboratories in Budapest (Uscom Budapest) by Uscom in September. Uscom Medical will function as a regional hub for Uscom Budapest manufactured goods and ensure delivery of Uscom products and service to the regional US and European markets.
Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Uscom is proudly Australian and expanding rapidly into export markets, and the establishment of Uscom UK is the next step in the globalization of our operations. This expansion establishes a European platform for our next generation of global growth.”
Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom Thor digital ultrasonic spirometry technologies. These premium digital devices changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and clinical and home care.
About Uscom
Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom Thor Spirometers. All Uscom devices are premium quality, and deploy innovative and practice leading technologies with FDA, CE and TGA regulatory approval, and which are currently being marketed into global distribution networks.
The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.
The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.
Uscom Thor spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide advanced pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma and monitoring pulmonary therapeutic compliance.
For more information, please visit: www.uscom.com.au
Uscom Contacts
Associate Professor Rob Phillips Executive Chairman [email protected]
Catherine Officer Company Secretary [email protected]